Market Overview:
The global FCGR1 antibody market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for monoclonal antibodies for research and development purposes, rising prevalence of cancer and other diseases, and growing investments by biopharmaceutical companies in the development of novel therapies. Based on type, the global FCGR1 antibody market is segmented into above 90%, above 95%, above 99%, and others. The majority of the revenue generated in this market is accounted for by products that have an affinity level greater than 90%. This segment is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. By application, biopharmaceutical companies are estimated to account for a major share of revenue generated in this market owing to their extensive R&D activities focused on developing novel therapies for various diseases such as cancer, autoimmune disorders, and infectious diseases.
Product Definition:
FCGR1 Antibody is a type of antibody which binds to the Fc fragment of IgG. It is important for the activation of complement and phagocytosis.
Above 90%:
The global FCGR1 antibody market size was valued at USD 955.0 million in 2018 and is expected to grow at a CAGR of XX% over the forecast period. The growth can be attributed to factors such as rising prevalence of rheumatoid arthritis, psoriasis, Crohn's disease, and cancer coupled with increasing geriatric population base across the globe.
Above 95%:
The Above 95% protein assay is a new method for the detection of proteins in urine. It has been designed to overcome limitations associated with traditional protein tests such as ELISA and RIA. The test is based on immunoassay technique and it can detect any level of Protein Urine Disease (PUD) including that caused by microscopic organisms such as mycoplasma, ureaplasma, bacteriuria, and urinary tract infection.
Application Insights:
The biopharmaceutical companies segment dominated the global FCGR1 antibody market in terms of revenue in 2017. This is attributed to the rising usage of antibodies for drug discovery and development. The Hospitals segment is expected to witness lucrative growth over the forecast period owing to increasing investments by governments for developing advanced healthcare facilities at a regional level, coupled with growing investments by private players for developing advanced healthcare facilities at a local level.
The bioscience research institutions are anticipated to register notable gains on account of increasing R&D activities pertaining to bio-production and biobanking across the globe. In addition, an increase in funding from government bodies and private investors has led towards increased R&D productivity which eventually benefits consumers through innovative products & services as well as enhanced technologies that can be commercialized quickly resulting in higher product adoption across various applications such as diagnostics tests & medical devices (excluding vaccines).
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The presence of a large number of biopharmaceutical companies and a high level of R&D activity are some factors responsible for its largest share. In addition, increasing government funding for research activities is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in healthcare expenditure by governments as well as private sectors coupled with rising awareness about cancer screening programs among people living in this region. Moreover, growing investments by pharmaceutical companies for drug development will further propel growth during the forecast period.
The Asia Pacific was followed by North America which accounted for approximately 27% revenue share globally owing to high R&D investment.
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the major growth drivers for the FCGR1 antibody market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing incidence rate of cancer is expected to drive demand for FCGR1 antibodies over the forecast period.
- Rising awareness about immunotherapy: The rising awareness about immunotherapy as a treatment option for various types of cancers is another key factor driving growth in the FCGR1 antibody market. Immunotherapy involves using substances that stimulate or restore immune system function to fight diseases such as cancer and has been shown to be more effective than traditional chemotherapy treatments in some cases. As a result, there is an increasing demand forFCGR1 antibodies for use in immunotherapy protocols across all tumor types
Scope Of The Report
Report Attributes
Report Details
Report Title
FCGR1 Antibody Market Research Report
By Type
Above 90%, Above 95%, Above 99%, Others
By Application
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
By Companies
Aviva Systems Biology Corporation(USA), St John's Laboratory Ltd(UK), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), R&D Systems(US), BioLegend(US), Thermo Fisher Scientific(US), USBiological(US), ProSci(US), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global FCGR1 Antibody Market Report Segments:
The global FCGR1 Antibody market is segmented on the basis of:
Types
Above 90%, Above 95%, Above 99%, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aviva Systems Biology Corporation(USA)
- St John's Laboratory Ltd(UK)
- Abbexa Ltd(UK)
- Abiocode(US)
- Boster Biological Technology(USA)
- Biobyt(UK)
- Bio-Rad(US)
- Bioss Antibodies(US)
- R&D Systems(US)
- BioLegend(US)
- Thermo Fisher Scientific(US)
- USBiological(US)
- ProSci(US)
- Genetex(US)
- Lifespan Biosciences(US)
- Novus Biologicals(US)
Highlights of The FCGR1 Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Above 90%
- Above 95%
- Above 99%
- Others
- By Application:
- Biopharmaceutical Companies
- Hospitals
- Bioscience Research Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the FCGR1 Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
FCGR1 antibody is a protein that is specifically expressed in the liver and it helps to clear the body of toxins. It also helps to regulate blood sugar levels.
Some of the major players in the fcgr1 antibody market are Aviva Systems Biology Corporation(USA), St John's Laboratory Ltd(UK), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), R&D Systems(US), BioLegend(US), Thermo Fisher Scientific(US), USBiological(US), ProSci(US), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US).
The fcgr1 antibody market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. FCGR1 Antibody Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. FCGR1 Antibody Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. FCGR1 Antibody Market - Supply Chain
4.5. Global FCGR1 Antibody Market Forecast
4.5.1. FCGR1 Antibody Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. FCGR1 Antibody Market Size (000 Units) and Y-o-Y Growth
4.5.3. FCGR1 Antibody Market Absolute $ Opportunity
5. Global FCGR1 Antibody Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. FCGR1 Antibody Market Size and Volume Forecast by Type
5.3.1. Above 90%
5.3.2. Above 95%
5.3.3. Above 99%
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global FCGR1 Antibody Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. FCGR1 Antibody Market Size and Volume Forecast by Application
6.3.1. Biopharmaceutical Companies
6.3.2. Hospitals
6.3.3. Bioscience Research Institutions
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global FCGR1 Antibody Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. FCGR1 Antibody Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global FCGR1 Antibody Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. FCGR1 Antibody Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global FCGR1 Antibody Demand Share Forecast, 2019-2026
9. North America FCGR1 Antibody Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America FCGR1 Antibody Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America FCGR1 Antibody Market Size and Volume Forecast by Application
9.4.1. Biopharmaceutical Companies
9.4.2. Hospitals
9.4.3. Bioscience Research Institutions
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America FCGR1 Antibody Market Size and Volume Forecast by Type
9.7.1. Above 90%
9.7.2. Above 95%
9.7.3. Above 99%
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America FCGR1 Antibody Demand Share Forecast, 2019-2026
10. Latin America FCGR1 Antibody Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America FCGR1 Antibody Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America FCGR1 Antibody Market Size and Volume Forecast by Application
10.4.1. Biopharmaceutical Companies
10.4.2. Hospitals
10.4.3. Bioscience Research Institutions
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America FCGR1 Antibody Market Size and Volume Forecast by Type
10.7.1. Above 90%
10.7.2. Above 95%
10.7.3. Above 99%
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America FCGR1 Antibody Demand Share Forecast, 2019-2026
11. Europe FCGR1 Antibody Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe FCGR1 Antibody Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe FCGR1 Antibody Market Size and Volume Forecast by Application
11.4.1. Biopharmaceutical Companies
11.4.2. Hospitals
11.4.3. Bioscience Research Institutions
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe FCGR1 Antibody Market Size and Volume Forecast by Type
11.7.1. Above 90%
11.7.2. Above 95%
11.7.3. Above 99%
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe FCGR1 Antibody Demand Share, 2019-2026
12. Asia Pacific FCGR1 Antibody Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific FCGR1 Antibody Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific FCGR1 Antibody Market Size and Volume Forecast by Application
12.4.1. Biopharmaceutical Companies
12.4.2. Hospitals
12.4.3. Bioscience Research Institutions
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific FCGR1 Antibody Market Size and Volume Forecast by Type
12.7.1. Above 90%
12.7.2. Above 95%
12.7.3. Above 99%
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific FCGR1 Antibody Demand Share, 2019-2026
13. Middle East & Africa FCGR1 Antibody Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa FCGR1 Antibody Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa FCGR1 Antibody Market Size and Volume Forecast by Application
13.4.1. Biopharmaceutical Companies
13.4.2. Hospitals
13.4.3. Bioscience Research Institutions
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa FCGR1 Antibody Market Size and Volume Forecast by Type
13.7.1. Above 90%
13.7.2. Above 95%
13.7.3. Above 99%
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa FCGR1 Antibody Demand Share, 2019-2026
14. Competition Landscape
14.1. Global FCGR1 Antibody Market: Market Share Analysis
14.2. FCGR1 Antibody Distributors and Customers
14.3. FCGR1 Antibody Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aviva Systems Biology Corporation(USA)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. St John's Laboratory Ltd(UK)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abbexa Ltd(UK)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abiocode(US)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boster Biological Technology(USA)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biobyt(UK)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bio-Rad(US)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bioss Antibodies(US)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. R&D Systems(US)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. BioLegend(US)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Thermo Fisher Scientific(US)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. USBiological(US)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. ProSci(US)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Genetex(US)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Lifespan Biosciences(US)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Novus Biologicals(US)
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
